With BRCA2+ and on high-dose transdermal estrogen, I happened to see a reply by Richard Wassersug hidden in a thread a long time ago, about the possible danger of t2E causing accelerated prostate cancer growth for those with BRCA+ disease.
I recently contacted him and he told me that he feels that this still holds, but acknowledges that there have been no clinical trials published that specifically document that.
The topic of the pros and cons of transdermal E2 and ADT is briefly summarized in the new European edition of the ADT book that he is the lead author on. The book came out in July, was reviewed by a number of MDs in Europe who treat PCa, and is officially endorsed by the European Association of Urology. I can highly recommend the book.
Written by
Purple-Bike
To view profiles and participate in discussions please or .
There are at least two well known and highly respected oncologists that deal a lot with BRCA2+ patients, Pamela Munster at UCSF and Susan Domchek at Phila Abramson Cancer Center. I contacted both and was told their focus is with women with breast and ovarian cancer. Unfortunately, not men with prostate cancer and neither was able to offer a recommendation. Maybe there are just too few of us male BRCA2+ patients that warrant such specialists?
Could be. My oncologist was not aware of the issue. I have been back and forth with Richard Wassersug including seeing documents he is referring to but they are very technical and hard to understand. He is not 100 % certain but says that there is a probable risk of accelerated prostate cancer with t2E for BRCA+. You are welcome to contact him over his email which is easily found on the internet.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.